Emerging digital technologies are one of the fastest growing sectors within the healthcare industry and are starting to reshape our perspective on how some diseases can be managed. Utilizing big data, sensors, artificial intelligence and software platforms provides the opportunity for improved disease management across multiple disease areas. Pharmaceutical companies are aware of this opportunity and are looking at ways in which these types of technologies can complement their products to offer “beyond the pill” solutions. Until now, many of the currently available digital technologies within the healthcare sector have targeted patients as the consumer and customer, meaning most technologies are paid by patients out-of-pocket or offered for free by manufacturers or pharmaceutical companies, a situation which is not ideal for uptake or innovation. In contrast, prescription drugs and most medical devices go through national reimbursement systems, thinking of the patient as the consumer and the payer or insurance company as the customer, this system allows universal access for patients and is something digital health technologies could also benefit from. Some Health Technology Assessment (HTA) bodies in Europe have started to look at how they can evaluate digital technology solutions alone or in combination with pharmaceutical products; however, access pathways remain unclear posing a hurdle for manufactures trying to deliver solutions and benefits to patients. Developing structured access and reimbursement pathways for digital health solutions will likely have a number of positive effects for the health care industry across multiple stakeholders types. Broader access will allow more patients to benefit, HTA bodies can have control on pricing and reimbursement of these type of solutions and additional appetite for innovation and investment within the sector will be generated.